Xeris Biopharma, Inc.
180 N LaSalle St
Suite 1600
Chicago
IL
60601
United States
Tel: 512-534-8340
Website: http://xerispharma.com/
Email: info@xerispharma.com
152 articles with Xeris Biopharma, Inc.
-
Xeris Biopharma to Participate in the SVB Securities Global Biopharma Conference 2023
2/2/2023
Xeris Biopharma, Inc. today announced that members of its senior management will hold 1x1 investor meetings and present an overview of the Company at the SVB Securities Global Biopharma Conference 2023, which is taking place in a virtual format.
-
Xeris Biopharma Announces FDA Grants Orphan-drug Exclusivity for Recorlev®
1/30/2023
Xeris Biopharma Holdings, Inc. today announced that the Food and Drug Administration (FDA) granted its subsidiary Xeris Pharmaceuticals, Inc., orphan-drug exclusivity (ODE) for Recorlev® (levoketoconazole) for the treatment of adult patients with endogenous Cushing’s syndrome for whom surgery is not an option or has not been curative.
-
Xeris Biopharma Updates Its Outlook For 2022
1/5/2023
Xeris Biopharma Holdings, Inc. today announced that, in connection with investor meetings the Company is planning to conduct next week in San Francisco, it has updated its outlook for full year 2022 expecting net product revenue to be at the top of its guidance range of $105 million to $110 million and its year-end cash balance to be above the previously announced range of $110 million to $120 million.
-
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
1/5/2023
Xeris Biopharma Holdings, Inc. announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 pm Pacific Time.
-
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism
12/15/2022
Xeris Biopharma Holdings, Inc. today announced that, based on feedback from a Type C meeting with the Food and Drug Administration (FDA), Xeris will proceed with a Phase II study in patients for its novel formulation of levothyroxine sodium (SC injection) as replacement therapy for hypothyroidism.
-
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
11/23/2022
Xeris Biopharma Holdings, Inc. today announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (Nasdaq: HZNP).
-
Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events
11/9/2022
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2022 and other corporate highlights.
-
Xeris Biopharma to Report Third Quarter 2022 Financial Results on November 9, 2022
11/2/2022
Xeris Biopharma Holdings, Inc. today announced that the Company will release its third quarter 2022 financial results before the open of the U.S. financial markets on Wednesday, November 9, 2022.
-
Xeris Biopharma Announces Results of the Extended Evaluation of Recorlev® (Levoketoconazole) From the Phase 3 Sonics Study Published in the European Journal of Endocrinology
11/1/2022
Xeris Biopharma Holdings, Inc. today announced that the European Journal of Endocrinology (EJE) published the extended evaluation (EE) results of the SONICS study (NCT01838551) evaluating longer-term effects of levoketoconazole on cortisol levels, biomarkers of Cushing’s syndrome (CS) comorbidities.
-
Xeris Biopharma Announces Positive Topline Phase 1 Clinical Data of Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121); Hosts Conference Call and Webcast
10/20/2022
Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced topline results from its Phase 1 study of subcutaneous levothyroxine in healthy adult volunteers.
-
Between top-notch academic institutions, solid venture capital funding, expanding lab space and governmental support, Chicago is emerging as a true hotbed for biotech growth.
-
As a leading biotech hub, the second city still ranks far below many other U.S. locations. That is starting to change, however, as new companies move into the heart of the BioMidwest region.
-
Xeris Biopharma Reports Second Quarter Financial Results and Upcoming Events
8/10/2022
Xeris Biopharma Holdings, Inc. today announced financial results for the second quarter and six months ended June 30, 2022 and upcoming events.
-
Xeris Biopharma to Report Second Quarter 2022 Financial Results on August 10, 2022
8/3/2022
Xeris Biopharma Holdings, Inc. today announced that the Company will release its second quarter 2022 financial results before the open of the U.S. financial markets on Wednesday, August 10, 2022.
-
Xeris’ Commercialization Partner for Ogluo®, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics
8/1/2022
Xeris Biopharma Holdings, Inc. today announced that Tetris Pharma—its commercialization partner for Ogluo in the UK, EEA, and Switzerland—will be acquired by Arecor Therapeutics.
-
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
5/12/2022
Xeris Biopharma Holdings, Inc. announced it is presenting new data on the burden of illness in Cushing’s syndrome and the double-blind, placebo-controlled LOGICS study of Recorlev® in CS during the Pituitary Disorders/Neuroendocrinology ePoster sessions at the American Association of Clinical Endocrinology Annual Meeting, May 12-14, 2022.
-
Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events
5/11/2022
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology today announced financial results for the first quarter and recent highlights.
-
Xeris Biopharma to Report First Quarter 2022 Financial Results on May 11, 2022
5/4/2022
Xeris Biopharma Holdings, Inc. today announced that the Company will release its first quarter 2022 financial results before the open of the U.S. financial markets on Wednesday, May 11, 2022.
-
Xeris Biopharma Announces Gvoke® Kit Is Now Available for the Treatment of Severe Hypoglycemia in Adults and Children With Diabetes Ages 2 And Above
3/16/2022
Xeris Biopharma Holdings, Inc. today announced that Gvoke® (glucagon injection) Kit is now available by prescription.
-
Xeris Announces $150M Senior Secured Term Loan Facility With Hayfin Capital
3/10/2022
Xeris Biopharma Holdings, Inc. today announced it has entered into a senior secured term loan agreement (“debt facility”) with funds managed by Hayfin Capital Management LLP (“Hayfin”) to provide Xeris with up to a total of $150 million of capital.